PEDRO PIEDRA to Single-Domain Antibodies
This is a "connection" page, showing publications PEDRO PIEDRA has written about Single-Domain Antibodies.
Connection Strength
0.300
-
Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021 01; 9(1):21-32.
Score: 0.176
-
Generation and Characterization of ALX-0171, a Potent Novel Therapeutic Nanobody for the Treatment of Respiratory Syncytial Virus Infection. Antimicrob Agents Chemother. 2016 01; 60(1):6-13.
Score: 0.124